3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 3
1
Phase 2
1
Status
Completed
11
Active not recruiting
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Interventions
Carboplatin
98
Cisplatin
95
pembrolizumab
91
Gemcitabine
81
Paclitaxel
79
Docetaxel
70
Capecitabine
64
Oxaliplatin
53
Fluorouracil
51
Specimen Handling
50
Magnetic Resonance Spectroscopy
49
Bevacizumab
49
Radiotherapy
48
Dexamethasone
45
Cyclophosphamide
45
Drug Therapy
39
Leucovorin
38
Doxorubicin
37
Pemetrexed
35
Irinotecan
34
Injections
30
Rituximab
29
Vincristine
28
Trastuzumab
26
Radiosurgery
26
Prednisone
26
Lenalidomide
25
Etoposide
25
130-nm albumin-bound paclitaxel
25
Radiation
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
Octreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled